EBITDA: Income before interest, taxes, depreciation and amortization.
Profound Medical (PROF) had EBITDA of $-8.72M for the most recently reported fiscal quarter, ending 2024-09-30.
| Income Statement Financials | |
$2.83M |
|
$-9.36M |
|
$1.03M |
|
$1.81M |
|
$11.82M |
|
$-8.99M |
|
$-0.20M |
|
$-9.19M |
|
$-9.19M |
|
$-9.36M |
|
$-9.36M |
|
$-9.36M |
|
$-9.36M |
|
$-8.99M |
|
|
EBITDA |
$-8.72M |
24.54M |
|
24.54M |
|
$-0.38 |
|
$-0.38 |
|
| Balance Sheet Financials | |
$40.88M |
|
$0.58M |
|
$1.35M |
|
$42.23M |
|
$6.68M |
|
$3.40M |
|
$4.49M |
|
$11.17M |
|
$31.06M |
|
$30.73M |
|
$31.06M |
|
24.66M |
|
| Cash Flow Statement Financials | |
$-17.81M |
|
-- |
|
$19.04M |
|
$26.21M |
|
$27.12M |
|
$0.91M |
|
$2.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.12 |
|
-- |
|
-- |
|
0.10 |
|
0.18 |
|
63.77% |
|
-317.37% |
|
-317.37% |
|
-- |
|
-324.40% |
|
-330.65% |
|
$-17.81M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.16 |
|
0.40 |
|
223.41 |
|
-30.14% |
|
-30.47% |
|
-22.17% |
|
-27.17% |
|
$1.26 |
|
$-0.73 |
|
$-0.73 |
|